Table 2 ASCO2023 updates from clinical studies of bispecific antibodies for multiple myeloma
Regimen | Teclistamab | Teclistamab | Elranatamab | Linvoseltamab | F182112 | Talquetamab | Teclistamab + Talquetamab | Talquetamab + Daratumumab |
|---|---|---|---|---|---|---|---|---|
Study | MajesTEC-1 | NA | MagnetisMM-3 | LINKER-MM1 | NTP-F182112-001 | MonumenTAL-1 | RedirecTT-1 | TRIMM-2 |
Disease | RRMM (without prior BCMA-directed therapies) | RRMM (with prior BCMA and GPRC5D-directed therapies) | RRMM (with and without prior BCMA-directed therapies) | RRMM (without prior BCMA-directed therapies) | RRMM (without prior BCMA-directed therapies) | RRMM (with and without prior T-cell-directed therapies) | RRMM | RRMM |
Pts | 165 | 24 | 123 | 252 | 16 | 288 | 63 | 65 |
mFU | 22 m | 1.3 m | 12.8 m (range, 0.2–22.7) | 2.3 m (200 mg); 4.7 m (50 mg) | 3.1 m (range, 0.9–11.7) | 14.9 m (QW); 8.6 m (Q2W); 11.8 m (prior T) | 14.4 m (range, 0.5–21.9) | 11.5 m (range, 1.0–27.3) |
ORR | NA | 60% | 61% (objective response rate) | 64% (200 mg); 50% (50 mg) | 43.8% (95% CI, 19.8–70.1) | 74% (QW); 73% (Q2W); 63% (prior T) | 84% | 78% |
CR (sCR) | 43% | NA | 31.7% | NA | NA | NA | 34% | 45% |
mDoR | 24 m (95% CI, 16.2–NR) | NR | 74.1% (95% CI, 60.5–83.6) at 12 m | NR | NA | NA | NR | NA |
mPFS | 12.5 m (95% CI, 8.8–17.2) | NR | 57.1% (95% CI, 47.2–65.9) at 12 m | NA | NA | 7.5 m (QW); 11.9 m (Q2W); 5.1 m (prior T) | NA | 19.4 m |
mOS | 21.9 m (95% CI, 16.0–NR) | NR | 62.0% (95% CI, 52.8–70.0) at 12 m | NA | NA | NA | NA | 93% at 12 m |
CRS | 72% | 41% | NA | 37% (200 mg); 53% (50 mg) | 81% | 79% (QW); 75% (Q2W); 77% (prior T) | 81% | 78% |
NAE/ICANS | ICANS: 3% | NAE: 13% | NA | ICANS ≥ G3: 2% (200 mg); 1% (50 mg) | NA | ICANS: 11% (QW); 11% (Q2W); 3% (prior T) | 2% | 5% |
Clinical trial number | NCT03145181/ NCT04557098 | NA (Retrospective study) | NCT04649359 | NCT03761108 | NCT04984434 | NCT03399799/ NCT04634552 | NCT04586426 | NCT04108195 |
Reference | [1] | [2] | [4] | [7] | [8] | [10] | [11] | [12] |